Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7598271 | SEBELA IRELAND LTD | Crystalline paroxetine methane sulfonate |
May, 2025
(2 years from now) | |
US8946251 | SEBELA IRELAND LTD | Method of treating thermoregulatory dysfunction with paroxetine |
Aug, 2026
(3 years from now) | |
US8658663 | SEBELA IRELAND LTD | Method of treating thermoregulatory disfunction with paroxetine |
Apr, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9393237 | SEBELA IRELAND LTD | Method of treating thermoregulatory dysfunction with paroxetine |
Aug, 2026
(3 years from now) |
Market Authorisation Date: 28 June, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: CAPSULE;ORAL
8
United States
3
Korea, Republic of
2
Denmark
2
Slovenia
2
Lithuania
2
Hungary
2
Croatia
2
Portugal
2
Cyprus
2
Spain
2
Poland
2
RS
2
Japan
2
European Union
1
Israel
1
Mexico
1
Australia
1
Russia
1
Norway
1
Singapore
1
Brazil
1
China
1
Ukraine
1
Canada
1
New Zealand
1
ME
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7598271 | SEBELA IRELAND LTD | Crystalline paroxetine methane sulfonate |
May, 2025
(2 years from now) |
Market Authorisation Date: 03 July, 2003
Treatment: NA
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic